These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11854826)

  • 1. Effect of Gender and Menopausal Status on the Pharmacokinetics of Tirilazad Mesylate in Healthy Subjects.
    Fleishaker JC; Hulst-Pearson LK; Peters GR
    Am J Ther; 1995 Aug; 2(8):553-560. PubMed ID: 11854826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Pharmacokinetics of the Neuroprotective Agent NBQX.
    Ingwersen SH; Ohrström JK; Petersen P; Drustrup J; Bruno L; Nordholm L
    Am J Ther; 1994 Dec; 1(4):296-303. PubMed ID: 11835103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacokinetics of tirilazad mesylate in healthy volunteers and stable subjects with mild liver cirrhosis.
    Pearson LK; Fleishaker JC; Peters GR
    Eur J Clin Pharmacol; 1996; 50(4):299-304. PubMed ID: 8803523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of age and gender on tirilazad pharmacokinetics in humans.
    Hulst LK; Fleishaker JC; Peters GR; Harry JD; Wright DM; Ward P
    Clin Pharmacol Ther; 1994 Apr; 55(4):378-84. PubMed ID: 8162663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of tirilazad and U-89678 in ischemic stroke patients receiving a loading regimen and maintenance regimen of 10 mg/kg/day of tirilazad.
    Fleishaker JC; Peters GR
    J Clin Pharmacol; 1996 Sep; 36(9):809-13. PubMed ID: 8889901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Food on the Pharmacokinetics and Pharmacodynamics of Torsemide.
    Kramer WG
    Am J Ther; 1995 Jul; 2(7):499-503. PubMed ID: 11850698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender does not affect the degree of induction of tirilazad clearance by phenobarbital.
    Fleishaker JC; Pearson LK; Peters GR
    Eur J Clin Pharmacol; 1996; 50(1-2):139-45. PubMed ID: 8739825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple-dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5-10 days in healthy volunteers.
    Fleishaker JC; Hulst LK; Peters GR
    Int J Clin Pharmacol Ther; 1994 May; 32(5):223-30. PubMed ID: 7921515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A.
    Fleishaker JC; Pearson LK; Pearson PG; Wienkers LC; Hopkins NK; Peters GR
    J Clin Pharmacol; 1999 Mar; 39(3):260-7. PubMed ID: 10073325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers.
    Fleishaker JC; Hulst LK; Peters GR
    Clin Pharmacol Ther; 1994 Oct; 56(4):389-97. PubMed ID: 7955800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Misoprostol and Prednisone Treatment of Lupus Nephritis.
    Belmont HM; Kitsis E; Skovron ML; Buyon J; McCullagh E; Abramson S
    Am J Ther; 1995 Dec; 2(12):928-932. PubMed ID: 11854810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single- and Multiple-Dose Pharmacokinetics of Reduced Metabolite (MDL 74,156) following Oral Administration of Dolasetron Mesylate to Normal Male Subjects.
    Shah A; Lanman R; Bhargava V; Weir S; Hahne W
    Am J Ther; 1996 May; 3(5):364-370. PubMed ID: 11862273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability.
    Fleishaker JC; Pearson PG; Wienkers LC; Pearson LK; Peters GR
    J Pharmacol Exp Ther; 1996 May; 277(2):991-8. PubMed ID: 8627582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tobramycin Serum Concentrations After Aerosol and Oral Administration in Cystic Fibrosis.
    Weber A; Williams-Warren J; Ramsey B; Smith AL
    Am J Ther; 1995 Feb; 2(2):81-87. PubMed ID: 11847533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Food Enhances Bioavailability of the New Antiarrhythmic Agent Tiracizine by Affecting its Hepatic First-Pass Metabolism: Evidence by Serum and Urine Metabolite Kinetics.
    Berndt A; Oertel R; Richter K; Gramatté T
    Am J Ther; 1994 Jun; 1(1):22-29. PubMed ID: 11835063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics in Non-Insulin-Dependent Diabetics of the Aldose Reductase Inhibitor, Zopolrestat.
    Inskeep PB; Reed AE; Connolly AG; Wilner KD; Vargas R; McMahon FG
    Am J Ther; 1995 Feb; 2(2):112-118. PubMed ID: 11847537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day.
    Fleishaker JC; Peters GR
    Int J Clin Pharmacol Ther; 1997 Jan; 35(1):28-32. PubMed ID: 9021439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple-Dose Pharmacokinetics of Ceftibuten in Healthy Adults and Geriatric Volunteers.
    Radwanski E; Teal M; Affrime M; Cayen M; Lin CC
    Am J Ther; 1994 Jun; 1(1):42-48. PubMed ID: 11835066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: I. Single-dose administration.
    Fleishaker JC; Peters GR; Cathcart KS
    J Clin Pharmacol; 1993 Feb; 33(2):175-81. PubMed ID: 8382708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation.
    Fleishaker JC; Pearson PG; Wienkers LC; Pearson LK; Moore TA; Peters GR
    J Pharmacol Exp Ther; 1998 Nov; 287(2):591-7. PubMed ID: 9808685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.